Deaths associated with Astellas Pharma’s gene therapy program for patients with X-linked Myotubular Myopathy underscore some of the risks of developing potential one-and-done treatment options for serious diseases.

epocrates, an athenahealth Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company recently brought on Matt Titus – an industry veteran of 13 years – to serve as the organization’s vice president, chief commercial officer.

Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the healthcare sector, announced that Andy Johnson has joined the company as Chief Information Officer (CIO). Johnson’s primary responsibilities will be to drive Real Chemistry’s information strategy, strengthen organizational systems and processes to best support the company’s people and clients, and innovate new ways to connect and collaborate.

AstraZeneca

Less than three months after Swedish Orphan Biovitrum AB (Sobi) agreed to be acquired by Advent International and GIC Special Investments for nearly $8 billion, the deal fell through after AstraZeneca withheld the company’s 8 percent stake from the buyout offer.

Dr. Bethany Valente, founder and managing partner of Tempo7 LLC, discusses the challenges that biotech and pharma-based businesses face as they work to create more efficient development time frames for product, therapy, or drug development. Dr. Valente says open innovation helps in resolving some of these challenges.

This free-to-attend event features tangible takeaways and tailored sessions to maximize e-prescribing and EHR technology engagement for optimal communication. Plus, benefit from Q&As with the speakers following the session.

Philip Morris continues to expand the tobacco giant’s ‘Beyond Nicotine’ strategy by acquiring Michigan-based OtiTopic, a company developing inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction.

Samsung BioLogics Co. Ltd. and Pfizer Inc. on May 12 denied a report that they were working together to produce in South Korea a Covid-19 vaccine developed by the U.S. drugmaker.

Fingerpaint named Bill Kwiatkowski as head of strategy in the full-service health and wellness marketing agency’s Conshohocken, Pa., office.

AstraZeneca

AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.